Clinical Approach to Vaginal Itching / Irritation

Comprehensive Practical Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of vaginal itching and irritation

Vulvovaginal pruritus (itching) and irritation represent one of the most common reasons for gynecological consultation, accounting for approximately 10 million office visits annually in the United States alone. Studies indicate that up to 75% of women will experience at least one episode of vulvovaginal candidiasis in their lifetime, and nearly 50% will have recurrent episodes. Vaginitis, encompassing infectious and non-infectious causes of vulvovaginal symptoms, affects women of all ages and has significant impacts on quality of life, sexual function, and psychological well-being.

Definition

Vulvovaginal pruritus refers to an unpleasant sensation localized to the vulva, vagina, or both that provokes the desire to scratch. Irritation encompasses burning, rawness, stinging, or discomfort in the vulvovaginal region. These symptoms may occur in isolation or together, and often accompany abnormal vaginal discharge, representing disruption of the normal vaginal ecosystem or underlying dermatological, infectious, or systemic conditions.

Key Epidemiology

Vulvovaginal candidiasis: Affects 75% of women at least once; 40-45% will have two or more episodes
Bacterial vaginosis: Prevalence of 29% in reproductive-age women in the United States
Trichomoniasis: Most common non-viral sexually transmitted infection globally; 3.7 million cases annually in the United States
Atrophic vaginitis: Affects 10-40% of postmenopausal women
Contact dermatitis: Accounts for up to 20-30% of chronic vulvar pruritus cases

Classification by Duration

Category	Duration	Common Causes	Clinical Significance
Acute	Less than 2 weeks	Vulvovaginal candidiasis, acute contact dermatitis, trichomoniasis, bacterial vaginosis	Usually infectious or irritant; good response to targeted therapy
Subacute	2 to 6 weeks	Partially treated infection, persistent contact irritation, early dermatoses	Consider treatment failure, ongoing exposure, or evolving dermatological condition
Chronic	Greater than 6 weeks	Recurrent vulvovaginal candidiasis, lichen sclerosus, lichen planus, atrophic vaginitis, vulvar dermatoses	Requires thorough investigation; often multifactorial; consider biopsy

Classification by Associated Discharge

With Abnormal Discharge

Suggests infectious etiology:

Vulvovaginal candidiasis — thick, white, “cottage cheese” discharge
Bacterial vaginosis — thin, gray-white, fishy odor
Trichomoniasis — frothy, yellow-green, malodorous
Desquamative inflammatory vaginitis — purulent discharge

Without Abnormal Discharge

Suggests non-infectious etiology:

Contact dermatitis — irritant or allergic
Lichen sclerosus — with white, atrophic changes
Lichen planus — erosive or papulosquamous
Atrophic vaginitis — minimal watery discharge
Psoriasis, eczema, or other dermatoses

Classification by Pattern and Timing

Pattern	Description	Suggests
Cyclic — premenstrual	Symptoms worsen in the week before menses	Vulvovaginal candidiasis (hormonally influenced); cyclic vulvovaginitis
Post-coital	Symptoms triggered or worsened after sexual intercourse	Contact sensitivity to condoms, lubricants, semen; trichomoniasis; trauma
Constant / persistent	Symptoms present continuously without fluctuation	Chronic dermatosis (lichen sclerosus, lichen planus); atrophic vaginitis
Recurrent episodic	Discrete symptomatic episodes with symptom-free intervals	Recurrent vulvovaginal candidiasis (4 or more episodes per year); recurrent bacterial vaginosis
Nocturnal predominance	Itching worse at night, disrupting sleep	Lichen sclerosus; pinworm infection (especially if perianal involvement)
Associated with new product	Onset temporally related to new hygiene product, medication, or clothing	Contact dermatitis — irritant or allergic

Classification by Location

Location	Primary Structures	Common Conditions
Vulvar only	Labia majora, labia minora, clitoris, vestibule	Contact dermatitis, lichen sclerosus, lichen planus, vulvar intraepithelial neoplasia
Vaginal only	Vaginal canal, introitus	Vulvovaginal candidiasis, bacterial vaginosis, trichomoniasis, atrophic vaginitis
Vulvovaginal	Both vulva and vagina	Vulvovaginal candidiasis with vulvar extension, desquamative inflammatory vaginitis
Perianal extension	Vulva extending to perianal skin	Lichen sclerosus (figure-of-eight pattern), pinworm infection, psoriasis

Key Concept — The Big Three Infectious Causes: Vulvovaginal candidiasis, bacterial vaginosis, and trichomoniasis account for approximately 90% of infectious vaginitis cases in reproductive-age women. However, up to 30% of women with vulvovaginal symptoms will have non-infectious causes, and many women with vaginal symptoms have normal vaginal flora on testing. Self-diagnosis is incorrect in up to 50% of cases, emphasizing the importance of clinical and laboratory evaluation.

Impact on Quality of Life

Physical Impact

Sleep disturbance from nocturnal pruritus
Dyspareunia and avoidance of intimacy
Secondary skin damage from scratching
Dysuria from vulvar inflammation

Psychological Impact

Anxiety and embarrassment
Depression with chronic symptoms
Fear of sexually transmitted infection
Concerns about hygiene or cleanliness

Social Impact

Relationship strain
Reduced sexual satisfaction
Work absenteeism
Healthcare-seeking behavior and costs

2. Pathophysiology and Mechanisms

Understanding the underlying mechanisms of vulvovaginal pruritus and irritation

The vulvovaginal region represents a unique anatomical and physiological environment with specialized defense mechanisms. Understanding the normal vaginal ecosystem and the pathophysiological mechanisms by which various conditions cause itching and irritation is essential for accurate diagnosis and effective treatment. The sensation of pruritus involves complex neuroimmune interactions, while the vaginal environment depends on a delicate balance of hormonal, microbial, and immunological factors.

The Normal Vaginal Ecosystem

Component	Normal State	Protective Function
Vaginal pH	3.8 to 4.5 (acidic)	Inhibits growth of pathogenic bacteria and yeast; maintained by lactobacilli
Lactobacillus species	Dominant flora (95% of bacteria)	Produce lactic acid, hydrogen peroxide, and bacteriocins; competitive exclusion of pathogens
Estrogen	Promotes glycogen deposition in epithelium	Glycogen serves as substrate for lactobacilli; maintains epithelial thickness
Vaginal epithelium	Stratified squamous, non-keratinized	Physical barrier; immune surveillance via Langerhans cells
Cervicovaginal secretions	Mucus, antimicrobial peptides, immunoglobulins	Pathogen trapping and neutralization; innate and adaptive immunity

The Pruritus Pathway

Component	Structure	Function in Pruritus
Pruritogens	Histamine, proteases, cytokines, neuropeptides	Chemical mediators that activate itch-sensing neurons
Sensory receptors	Free nerve endings, C-fibers in dermis and epidermis	Detect pruritogenic stimuli; express histamine receptors, PAR-2, TRPV1
Afferent pathway	Pudendal nerve, posterior cutaneous nerve of thigh	Transmit itch signals from vulva to spinal cord (S2-S4)
Spinal cord processing	Dorsal horn neurons (lamina I)	Itch-specific neurons; modulated by descending inhibition
Central processing	Spinothalamic tract to thalamus, somatosensory cortex	Conscious perception of itch; emotional and cognitive components
Scratch reflex	Motor cortex, spinal motor neurons	Behavioral response; provides temporary relief but can perpetuate itch-scratch cycle

Key Mediators of Vulvovaginal Pruritus

Histamine

Source: Mast cells, basophils

Mechanism: Binds H1 and H4 receptors on sensory neurons; causes vasodilation and increased permeability

Clinical relevance: Important in allergic contact dermatitis; explains partial response to antihistamines

Proteases

Source: Candida species, inflammatory cells, bacteria

Mechanism: Activate protease-activated receptor-2 (PAR-2) on keratinocytes and nerve fibers

Clinical relevance: Major mediator in candidiasis; explains itch without significant histamine release

Cytokines

Source: Keratinocytes, immune cells

Mechanism: IL-31, IL-4, IL-13 directly activate sensory neurons; Th2-driven inflammation

Clinical relevance: Chronic inflammatory conditions; lichen planus and atopic dermatitis

How Specific Conditions Cause Pruritus and Irritation

Condition	Mechanism	Treatment Implication
Vulvovaginal candidiasis	Candida hyphae invade epithelium and release proteases (secreted aspartyl proteases) that activate PAR-2 receptors; local inflammatory response with IL-1β, IL-8 release; disruption of epithelial barrier	Antifungals reduce organism burden and protease production; topical steroids can provide symptomatic relief
Bacterial vaginosis	Overgrowth of anaerobic bacteria produces amines (putrescine, cadaverine, trimethylamine) causing irritation and fishy odor; elevated pH (greater than 4.5) disrupts epithelial defenses; biofilm formation	Antibiotics reduce anaerobic overgrowth; restoration of lactobacilli may prevent recurrence
Trichomoniasis	Trichomonas vaginalis adheres to vaginal epithelium via adhesins; releases cysteine proteases causing cytolysis; triggers robust inflammatory response with neutrophil infiltration; “strawberry cervix” from punctate hemorrhages	Nitroimidazoles kill organism; partner treatment essential to prevent reinfection
Atrophic vaginitis	Estrogen deficiency leads to decreased glycogen, loss of lactobacilli, elevated pH; epithelial thinning with decreased lubrication; increased susceptibility to trauma and infection; reduced blood flow	Local estrogen therapy restores epithelial integrity and vaginal ecosystem; non-hormonal moisturizers provide symptomatic relief
Contact dermatitis (irritant)	Direct cytotoxic damage to keratinocytes from chemical irritants (soaps, douches); disruption of skin barrier; release of pro-inflammatory cytokines (IL-1α, TNF-α) without immune sensitization	Identification and avoidance of irritant; barrier repair with emollients; topical steroids for inflammation
Contact dermatitis (allergic)	Type IV delayed hypersensitivity reaction; allergen presented to T-cells by Langerhans cells; sensitized T-cells release cytokines on re-exposure causing inflammation; common allergens include fragrances, preservatives, latex	Allergen identification via patch testing; strict avoidance; topical steroids for acute flares
Lichen sclerosus	Autoimmune-mediated inflammation with lymphocytic infiltrate; progressive dermal collagen homogenization; loss of elastic fibers; epithelial atrophy alternating with hyperkeratosis; altered local cytokine milieu	Potent topical corticosteroids suppress inflammation; requires long-term maintenance therapy; surveillance for squamous cell carcinoma
Lichen planus	T-cell mediated autoimmune attack on basal keratinocytes; apoptosis of basal cells; interface dermatitis; may be erosive causing significant pain; associated with scarring and architectural distortion	Topical and sometimes systemic immunosuppression; management of erosions; surveillance for malignancy

The Itch-Scratch Cycle in Vulvar Disease

Understanding the Vicious Cycle:

Initial stimulus: Pruritogen (infection, allergen, irritant) activates sensory neurons
Scratching behavior: Provides temporary relief via gate control mechanism (A-beta fiber activation inhibits C-fiber transmission)
Epithelial damage: Scratching causes mechanical trauma to skin barrier
Secondary inflammation: Damaged keratinocytes release more cytokines and pruritogens
Neural sensitization: Chronic inflammation lowers itch threshold; peripheral and central sensitization
Lichenification: Chronic rubbing leads to epithelial thickening, which itself becomes pruritic

Clinical Pearl: Breaking the itch-scratch cycle is essential in managing chronic vulvar pruritus. This may require sedating antihistamines at night, barrier protection, and addressing psychological factors.

Factors That Disrupt the Vaginal Ecosystem

Host Factors

Hormonal changes: Menstruation, pregnancy, menopause, hormonal contraceptives
Diabetes mellitus: Elevated vaginal glucose favors Candida growth
Immunosuppression: HIV, chemotherapy, corticosteroids
Antibiotics: Disrupt lactobacillus dominance
Genetic factors: Mannose-binding lectin deficiency; polymorphisms in pattern recognition receptors

Behavioral and Environmental Factors

Sexual activity: Semen elevates vaginal pH; new partners alter flora
Douching: Disrupts normal flora; increases bacterial vaginosis risk
Hygiene products: Soaps, wipes, sprays cause irritation
Clothing: Non-breathable synthetic underwear, tight clothing
Moisture: Prolonged wetness from sweat, urine, or discharge

Often Overlooked Mechanism

Vulvodynia and Central Sensitization: Some women with chronic vulvovaginal symptoms have no identifiable infectious or dermatological cause. In these cases, peripheral nerve injury or inflammation may trigger central sensitization — a state in which spinal cord and brain neurons become hyperexcitable. This leads to allodynia (pain from normally non-painful stimuli) and hyperalgesia. The vulva has the highest density of nerve endings in the body, making it particularly susceptible to sensitization syndromes. Recognition of this mechanism is crucial because these patients do not respond to antifungals, antibiotics, or even topical steroids, but may benefit from neuromodulating medications (tricyclic antidepressants, gabapentinoids) and pelvic floor physical therapy.

Vaginal pH and Its Clinical Significance

pH Range	Clinical State	Associated Conditions
3.8 – 4.5	Normal (reproductive age)	Healthy vaginal ecosystem; vulvovaginal candidiasis can occur at normal pH
Greater than 4.5	Elevated pH	Bacterial vaginosis, trichomoniasis, atrophic vaginitis, recent intercourse, menstrual blood, cervical mucus
5.0 – 7.0	Prepubertal and postmenopausal baseline	Low estrogen states; decreased lactobacilli; increased susceptibility to infection

3. History Taking

A comprehensive approach to eliciting the vulvovaginal symptom history

Red Flags — Require Urgent Evaluation

Vulvar ulceration or erosion — Consider herpes simplex virus, syphilis, Behçet disease, or malignancy
Palpable vulvar mass or nodule — Rule out vulvar carcinoma, especially in elderly or with lichen sclerosus
Persistent unilateral symptoms — Asymmetric findings raise concern for neoplasia
Bleeding (non-menstrual) — May indicate cervical or vulvar pathology

Systemic symptoms — Fever, weight loss, or lymphadenopathy suggest systemic disease or advanced malignancy
Failure to respond to appropriate treatment — Reconsider diagnosis; biopsy may be indicated
Architectural distortion — Loss of normal anatomy (labial fusion, clitoral burial) suggests chronic dermatosis requiring specialist referral
Immunocompromised patient — Higher risk for atypical infections and malignancy

Systematic History: The “VULVAR” Approach

Use the mnemonic “VULVAR” to ensure comprehensive history taking for vulvovaginal pruritus and irritation:

V — Validate and characterize: When did it start? Constant or intermittent? Itching, burning, or both? Rate severity 0-10.
U — Understand the discharge: Is there discharge? Color, consistency, odor? Amount and timing?
L — Location and radiation: Where exactly? Vulva, vagina, or both? Perianal involvement? Unilateral or bilateral?
V — Variations and triggers: Relationship to menses, intercourse, products, clothing? Worse at night? Seasonal pattern?
A — Associated symptoms: Dyspareunia, dysuria, pelvic pain? Skin lesions elsewhere? Oral ulcers? Joint pain?
R — Risk factors and responses: Sexual history, diabetes, medications, prior treatments and their effects?

Targeted Questions by Suspected Cause

Suspected Cause	Key Features	Ask This Question
Vulvovaginal candidiasis	Intense itching, thick white discharge, vulvar erythema and edema	“Is the itching your main symptom? Do you notice a thick, white discharge like cottage cheese? Does it worsen before your period?”
Bacterial vaginosis	Fishy odor, thin gray discharge, minimal itching	“Do you notice a fishy smell, especially after intercourse or during your period? Is the discharge thin and grayish?”
Trichomoniasis	Frothy yellow-green discharge, strong odor, dysuria	“Is the discharge frothy or bubbly? Yellow or greenish? Do you have burning with urination? Any new sexual partners?”
Contact dermatitis	Temporal relationship to products, well-demarcated erythema	“Have you started using any new products — soaps, detergents, wipes, pads, lubricants, or condoms? Did the symptoms start after this?”
Atrophic vaginitis	Postmenopausal, dryness, dyspareunia, light spotting	“Do you experience vaginal dryness? Is intercourse painful? Have you had any light bleeding or spotting? Are you postmenopausal or breastfeeding?”
Lichen sclerosus	Severe nocturnal itching, white patches, dyspareunia, constipation	“Is the itching worse at night and keeping you awake? Have you noticed any white patches or skin changes? Any difficulty with bowel movements or painful intercourse?”
Lichen planus	Pain predominates over itch, erosions, oral lesions	“Is pain more of a problem than itching? Have you noticed any sores or raw areas? Do you have any mouth sores or a lacy white pattern inside your cheeks?”
Recurrent vulvovaginal candidiasis	Four or more episodes per year, symptom-free intervals	“How many times have you had these symptoms in the past year? Do you have completely symptom-free periods between episodes?”
Psoriasis	Well-demarcated plaques, family history, other body sites	“Do you have psoriasis elsewhere on your body — scalp, elbows, knees? Does anyone in your family have psoriasis?”
Pinworm infection (Enterobius)	Perianal and vulvar itching worse at night, especially in those with children	“Is the itching worst around the anus? Does it wake you at night? Are there young children in the household who might have similar symptoms?”

Sexual and Gynecological History

Sexual History (5 Ps Framework)

Partners: Number in past year, gender of partners, new partners
Practices: Vaginal, oral, anal intercourse; use of sex toys
Protection: Condom use, type of contraception, lubricants used
Past STIs: History of sexually transmitted infections, treatments received
Pregnancy prevention/plans: Current contraception, pregnancy status

Key questions:

“Does your partner have any symptoms — discharge, rash, or itching?”
“Do symptoms occur after intercourse?”
“Is intercourse painful? If so, is it at entry or with deep penetration?”

Gynecological History

Menstrual history: Last menstrual period, regularity, relationship of symptoms to cycle
Menopausal status: Perimenopausal symptoms, hormone therapy use
Obstetric history: Pregnancies, deliveries, perineal trauma
Cervical screening: Last Pap smear, HPV status, any abnormal results
Previous vulvovaginal conditions: Prior yeast infections, bacterial vaginosis, herpes
Previous treatments: What has been tried? What worked or did not work?

Medication and Product History

Medications That Affect Vulvovaginal Health

Antibiotics — Disrupt vaginal flora, predispose to candidiasis
Corticosteroids (systemic) — Immunosuppression, candidiasis risk
Hormonal contraceptives — May alter vaginal environment
Tamoxifen — Can cause atrophic changes
Aromatase inhibitors — Cause profound estrogen depletion
Chemotherapy — Immunosuppression, mucositis
Isotretinoin — Mucosal dryness
Antihistamines — Vaginal dryness as side effect

Products to Ask About

Soaps and body washes: Fragranced products, antibacterial soaps
Feminine hygiene products: Douches, sprays, wipes, deodorants
Menstrual products: Pads, tampons, menstrual cups (materials, fragrances)
Laundry products: Detergents, fabric softeners, dryer sheets
Underwear: Synthetic materials, thongs, tight-fitting
Sexual products: Lubricants, spermicides, condoms (latex allergy)
Topical treatments: Over-the-counter antifungals, home remedies
Toilet paper: Colored or fragranced varieties

Medical and Social History

Category	Relevance	Key Questions
Diabetes mellitus	Increased glucose in vaginal secretions favors Candida; recurrent candidiasis may be presenting symptom	“Do you have diabetes? Is it well controlled? When was your last HbA1c checked?”
Immunocompromise	HIV, chemotherapy, transplant — increased infection risk, atypical presentations	“Do you have any conditions affecting your immune system? Are you on any immunosuppressive medications?”
Autoimmune diseases	Association with lichen sclerosus, lichen planus; may have other autoimmune conditions	“Do you have thyroid disease, vitiligo, or any autoimmune conditions?”
Skin conditions	Psoriasis, eczema, lichen planus may affect vulva	“Do you have any skin conditions like psoriasis or eczema? Do you have rashes elsewhere?”
Gastrointestinal symptoms	Crohn disease can cause vulvar involvement; constipation common in lichen sclerosus	“Do you have any bowel conditions like Crohn disease? Any constipation or painful bowel movements?”
Urinary symptoms	Incontinence causes moisture; urinary tract infections may coexist	“Do you have any urine leakage? Burning with urination? Frequent urinary tract infections?”
Psychological factors	Chronic symptoms cause distress; stress can exacerbate symptoms; itch-scratch cycle	“How are these symptoms affecting your mood and daily life? How are things at home and at work?”

Treatment History Assessment

Essential Questions About Prior Treatments

Understanding what has been tried — and the response — provides crucial diagnostic information:

What treatments have you tried? (Over-the-counter antifungals, prescriptions, home remedies)
Did any treatment provide relief? (Complete, partial, or none)
How long did you use each treatment? (Adequate duration is essential)
Did symptoms return after stopping treatment? (Recurrence pattern)
Were any treatments prescribed based on testing or empirically? (Prior confirmation of diagnosis)
Did any treatment make symptoms worse? (May suggest contact sensitivity)

Diagnostic Pearl: Improvement with antifungals suggests candidiasis. Improvement with antibiotics suggests bacterial vaginosis or trichomoniasis. Improvement with topical steroids suggests dermatosis or contact dermatitis. Failure of all treatments should prompt reconsideration of diagnosis.

4. Physical Examination

A systematic approach to vulvovaginal examination for pruritus and irritation

Systematic Framework: Use the “Outside-to-Inside” approach for complete examination of patients presenting with vulvovaginal pruritus and irritation. Always examine in good lighting, ideally with a magnifying lamp or colposcope for detailed vulvar assessment.

General Inspection

General appearance: Signs of systemic illness, nutritional status, mobility (relevant for hygiene)
Skin elsewhere: Examine for psoriatic plaques, eczema, lichen planus (skin and oral), vitiligo
Inguinal lymph nodes: Lymphadenopathy may indicate infection (herpes, syphilis) or malignancy
Body habitus: Obesity may predispose to intertrigo and moisture-related issues
Mental state: Note anxiety, distress, or signs of depression related to chronic symptoms

Vital Signs

Vital Sign	What to Look For	Clinical Significance
Temperature	Fever (greater than 38°C / 100.4°F)	Suggests pelvic inflammatory disease, tubo-ovarian abscess, or systemic infection; uncommon in simple vaginitis
Heart Rate	Tachycardia	May accompany fever or indicate significant pain/distress
Blood Pressure	Usually normal	Elevated in pain or anxiety; hypotension rare unless septic
Body Mass Index	Obesity (BMI greater than 30)	Predisposes to intertrigo, moisture retention, and recurrent candidiasis

External Genital Examination

Position the patient in lithotomy position with adequate lighting. A systematic approach examines all structures:

Anatomy to Examine Systematically

Vulvar Structures

Mons pubis
Labia majora (outer surface and inner surface)
Labia minora
Clitoral hood and clitoris
Interlabial sulci
Vestibule (Hart’s line to hymenal ring)
Urethral meatus
Skene gland openings
Bartholin gland openings
Fourchette and perineal body
Perianal skin

What to Document

Color changes: Erythema, hypopigmentation (white), hyperpigmentation
Texture: Lichenification, atrophy, hyperkeratosis
Architecture: Labial fusion, clitoral phimosis, introital narrowing
Lesions: Papules, plaques, erosions, ulcers, fissures
Excoriations: Evidence of scratching
Discharge: Presence at introitus, character
Edema: Labial swelling
Symmetry: Unilateral findings raise concern for neoplasia

Key External Findings by Condition

Condition	Characteristic External Findings
Vulvovaginal candidiasis	Vulvar erythema and edema; satellite papulopustules at periphery; fissures in interlabial folds; thick white discharge at introitus; excoriations from scratching
Contact dermatitis	Well-demarcated erythema corresponding to area of contact; may see vesicles (acute allergic); lichenification (chronic); edema; distribution follows exposure pattern
Lichen sclerosus	Porcelain-white, crinkled “cigarette paper” skin; figure-of-eight pattern involving vulva and perianal area; ecchymoses; fissures; labial fusion; clitoral hood phimosis; architectural distortion
Lichen planus	Erosions with white, reticulated (Wickham striae) border; glazed erythema; scarring with labial agglutination; vaginal involvement common; check oral mucosa for similar findings
Atrophic vaginitis	Pale, thin vulvar and vaginal epithelium; loss of labial fullness; sparse pubic hair; decreased elasticity; petechiae; introital narrowing
Psoriasis	Well-demarcated, symmetric, salmon-pink plaques; minimal scale in intertriginous areas (inverse psoriasis); may see typical plaques elsewhere
Lichen simplex chronicus	Thickened, lichenified skin with accentuated skin markings; hyperpigmentation or hypopigmentation; unilateral or bilateral; result of chronic scratching
Herpes simplex (primary)	Clusters of vesicles on erythematous base; painful ulcerations; inguinal lymphadenopathy; may have systemic symptoms

Vestibular Assessment (Q-tip Test)

Cotton Swab Vestibular Mapping

For patients with vulvar pain, burning, or entry dyspareunia, perform vestibular mapping:

Use a moistened cotton swab to gently touch around the vestibule in a clock-face pattern
Ask the patient to rate pain at each site (0-10 scale)
Positive test: Reproducible, localized pain with light touch, particularly at the posterior vestibule (5, 6, 7 o’clock positions)
Suggests: Vestibulodynia (formerly vulvar vestibulitis syndrome) — a subset of vulvodynia
Allodynia (pain from normally non-painful stimulus) indicates peripheral or central sensitization

Speculum Examination

Use warm, water-lubricated speculum (avoid lubricants that may interfere with testing). In atrophic or anxious patients, use smallest speculum and proceed gently.

Vaginal Assessment

Finding	Description	Associated Conditions
Discharge character	Note color, consistency, amount, odor, location	White curd-like (candidiasis); thin gray homogeneous (bacterial vaginosis); frothy yellow-green (trichomoniasis); purulent (desquamative inflammatory vaginitis)
Vaginal wall appearance	Color, texture, moisture, lesions	Erythematous, edematous (candidiasis, trichomoniasis); pale, thin, dry (atrophic); erosions with synechiae (erosive lichen planus)
Cervical appearance	Note color, discharge, lesions, friability	“Strawberry cervix” with punctate hemorrhages (trichomoniasis); mucopurulent cervicitis (chlamydia, gonorrhea)
Vaginal rugae	Normal transverse folds	Present in estrogenized vagina; absent or flattened in atrophy
Vaginal pH	Test with pH paper on lateral vaginal wall	Normal 3.8-4.5; elevated (greater than 4.5) in bacterial vaginosis, trichomoniasis, atrophy

Bimanual Examination

Cervical motion tenderness: Absent in simple vaginitis; present suggests pelvic inflammatory disease
Uterine tenderness: Should be non-tender; tenderness suggests endometritis
Adnexal masses or tenderness: Rule out tubo-ovarian abscess if febrile with vaginitis symptoms
Pelvic floor assessment: Note hypertonicity, tenderness of levator ani muscles (relevant in vulvodynia)

Expected Findings by Etiology

Condition	External Vulva	Vaginal Findings	Cervix	pH
Vulvovaginal candidiasis	Erythema, edema, satellite lesions, fissures	Thick, white, curd-like discharge adherent to walls; erythema	Usually normal	Normal (less than 4.5)
Bacterial vaginosis	Usually normal	Thin, homogeneous, gray-white discharge coating walls; fishy odor	Normal	Elevated (greater than 4.5)
Trichomoniasis	Erythema, edema possible	Frothy, yellow-green, malodorous discharge; erythematous vaginal walls	“Strawberry cervix” (punctate hemorrhages) in 2-5%	Elevated (greater than 4.5)
Atrophic vaginitis	Pale, thin, dry; labial atrophy	Pale, thin, smooth walls; loss of rugae; petechiae; scant discharge	Pale, may be friable	Elevated (5.0-7.0)
Contact dermatitis	Well-demarcated erythema; edema; may have vesicles	Usually normal unless intravaginal product used	Normal	Normal
Lichen sclerosus	White, atrophic plaques; architectural changes; fissures	Spares vagina (stops at Hart’s line)	Normal	Normal
Lichen planus (erosive)	Erosions, Wickham striae, scarring	Erosions, synechiae, vaginal stenosis possible	May be involved	May be elevated

Additional Examinations to Consider

Oral Examination

Examine oral mucosa for:

Wickham striae: Lacy white pattern on buccal mucosa — lichen planus
Erosions: Oral erosive lichen planus
Aphthous ulcers: Consider Behçet disease if genital ulcers present
Thrush: Oral candidiasis may indicate immunocompromise

Skin Examination

Survey entire skin for:

Psoriatic plaques: Scalp, elbows, knees, nails
Lichen planus: Wrists, ankles, shins — violaceous, polygonal papules
Vitiligo: Associated with lichen sclerosus
Eczema: Flexural areas

Important Teaching Point

Normal examination is possible! Several important causes of vulvovaginal pruritus and irritation may present with minimal or no visible findings:

Mild bacterial vaginosis: Vulva appears normal; diagnosis made on vaginal discharge and testing
Early candidiasis: May have symptoms before visible erythema develops
Vulvodynia: By definition, examination is normal or near-normal despite significant symptoms
Contact dermatitis (resolved): Examination may be normal between exposures
Cyclic vulvovaginitis: May be normal when examined outside symptomatic phase

Clinical Pearl: A normal examination does not exclude significant pathology. Laboratory testing, careful history, and sometimes empiric treatment trials are needed when examination is unrevealing. Consider having the patient return during a symptomatic episode for re-examination.

Documentation Template for Vulvar Examination

Suggested Documentation Format:

External genitalia: Mons pubis [normal/abnormal]. Labia majora [symmetric/asymmetric], [normal color/erythematous/hypopigmented], [normal texture/lichenified/atrophic]. Labia minora [present/resorbed], [normal/fused]. Clitoral hood [normal/phimotic]. Vestibule [normal/erythematous], [non-tender/tender to light touch at ___ o’clock]. Perineum [intact/scarred]. Perianal area [normal/involved].

Vaginal examination: Discharge [none/white curd-like/thin gray/frothy yellow-green], [no odor/fishy odor]. Vaginal walls [pink, rugated/pale, smooth/erythematous]. pH [value].

Cervix: [Normal appearance/strawberry cervix/mucopurulent discharge]. No cervical motion tenderness.

Bimanual: Uterus [size, position, tenderness]. Adnexa [non-tender, no masses/findings].

5. Differential Diagnosis

Systematic approach organized by probability and clinical features

Acute Vulvovaginal Pruritus and Irritation (Duration: Less Than 2 Weeks)

Probability	Condition	Key Features	Red Flags
COMMON (approximately 70%)	Vulvovaginal candidiasis	Intense pruritus, thick white discharge, vulvar erythema and edema, premenstrual worsening	Recurrent episodes (4 or more per year) may indicate diabetes or immunocompromise
COMMON	Bacterial vaginosis	Fishy odor (especially after intercourse), thin gray discharge, minimal itching, elevated pH	Recurrent bacterial vaginosis increases risk of sexually transmitted infections and preterm birth
COMMON	Irritant contact dermatitis	Temporal relationship to new product, burning more than itching, well-demarcated erythema	Severe blistering or erosions suggest more significant reaction
LESS COMMON (approximately 20%)	Trichomoniasis	Frothy yellow-green discharge, strong odor, dysuria, new sexual partner	Screen for other sexually transmitted infections; partner treatment essential
LESS COMMON	Allergic contact dermatitis	Severe pruritus, edema, may have vesicles, history of prior exposure to allergen	Anaphylaxis possible with severe latex allergy
LESS COMMON	Herpes simplex virus (primary)	Painful vesicles and ulcerations, dysuria, inguinal lymphadenopathy, flu-like symptoms	Urinary retention may require catheterization; consider disseminated herpes if immunocompromised
UNCOMMON BUT SERIOUS (approximately 10%)	Pelvic inflammatory disease	Lower abdominal pain, fever, cervical motion tenderness, abnormal discharge	Tubo-ovarian abscess; sepsis; long-term fertility consequences
UNCOMMON BUT SERIOUS	Primary syphilis	Painless vulvar ulcer (chancre), inguinal lymphadenopathy	Highly infectious; screen for HIV and other sexually transmitted infections

Chronic Vulvovaginal Pruritus and Irritation (Duration: Greater Than 6 Weeks)

Step-by-Step Approach to Chronic Vulvovaginal Symptoms:

Step 1: Rule out persistent or recurrent infection — Has candidiasis, bacterial vaginosis, or trichomoniasis been properly treated and confirmed resolved?
Step 2: Assess for contact factors — Is there ongoing exposure to irritants or allergens? Review all products used.
Step 3: Consider the “Big Four” chronic causes — Lichen sclerosus, lichen planus, atrophic vaginitis, and lichen simplex chronicus
Step 4: If diagnosis remains unclear after initial workup, vulvar biopsy is often indicated

Probability	Condition	Approximate Frequency	Key Distinguishing Features
COMMON	Recurrent vulvovaginal candidiasis	5-8% of women	Four or more documented episodes per year; symptom-free intervals; often responds to antifungals then recurs; associated with diabetes, immunosuppression
COMMON	Lichen sclerosus	1 in 300-1000 women	White, atrophic plaques; figure-of-eight pattern; severe nocturnal pruritus; architectural changes (labial fusion, clitoral phimosis); bimodal age distribution
COMMON	Lichen simplex chronicus	Common secondary change	Lichenification from chronic scratching; thickened skin with accentuated markings; often unilateral; may obscure underlying condition
COMMON	Atrophic vaginitis (genitourinary syndrome of menopause)	10-40% of postmenopausal women	Postmenopausal or hypoestrogenic state; vaginal dryness; dyspareunia; pale, thin epithelium; elevated pH; loss of rugae
LESS COMMON	Lichen planus	1-2% prevalence	Pain predominates over itch; erosions with white, lacy border; vaginal involvement with scarring; oral lesions in 50%; middle-aged women
LESS COMMON	Vulvar psoriasis	2-5% of psoriasis patients	Well-demarcated salmon-pink plaques; minimal scale in flexural areas; psoriasis elsewhere on body; family history
LESS COMMON	Vulvodynia / vestibulodynia	8-10% of women	Chronic pain, burning, or rawness without visible findings; allodynia on Q-tip test; normal laboratory studies; diagnosis of exclusion
LESS COMMON	Desquamative inflammatory vaginitis	Rare	Purulent vaginal discharge; vaginal erythema; elevated pH; increased parabasal cells; exclusion of infection; responds to clindamycin or steroids
UNCOMMON BUT SERIOUS	Vulvar intraepithelial neoplasia	2-3 per 100,000 women	Persistent lesion not responding to treatment; pigmented or raised lesion; associated with HPV or lichen sclerosus; biopsy required
UNCOMMON BUT SERIOUS	Vulvar squamous cell carcinoma	Incidence increases with age	Persistent ulcer or mass; often in setting of chronic lichen sclerosus; unilateral; elderly patients; biopsy essential
UNCOMMON BUT SERIOUS	Extramammary Paget disease	Rare	Well-demarcated, erythematous, eczematous plaque; chronic, treatment-resistant; elderly women; may indicate underlying adenocarcinoma

Anatomical Approach to Differential Diagnosis

Vulva Only (Spares Vagina)

Lichen sclerosus

Contact dermatitis

Lichen simplex chronicus

Vulvar psoriasis

Vulvar intraepithelial neoplasia

Extramammary Paget disease

Vagina Only (Spares Vulva)

Bacterial vaginosis

Atrophic vaginitis

Desquamative inflammatory vaginitis

Cervicitis (discharge perceived as vaginal)

Retained foreign body

Vulvovaginal (Both Involved)

Vulvovaginal candidiasis

Trichomoniasis

Erosive lichen planus

Severe atrophic changes

Herpes simplex virus

Vulva with Perianal Extension

Lichen sclerosus (figure-of-eight)

Pinworm infection (Enterobius)

Inverse psoriasis

Crohn disease (vulvar)

Streptococcal perianal dermatitis

Age-Based Considerations

Age Group	Common Causes	Special Considerations
Reproductive age (18-45)	Vulvovaginal candidiasis, bacterial vaginosis, trichomoniasis, contact dermatitis, herpes simplex virus	Consider pregnancy status; screen for sexually transmitted infections; cyclic symptoms suggest hormonal influence
Perimenopausal (45-55)	All of above plus early atrophic changes, lichen sclerosus (second peak)	Fluctuating estrogen may cause variable symptoms; consider hormone therapy response
Postmenopausal (greater than 55)	Atrophic vaginitis, lichen sclerosus, lichen planus, vulvar malignancy	Higher index of suspicion for malignancy; biopsy any persistent or suspicious lesions; candidiasis suggests diabetes

Drug-Induced Vulvovaginal Symptoms

Drug or Drug Class	Mechanism	Characteristics	Management
Antibiotics (broad-spectrum)	Disruption of lactobacillus-dominant flora	Candidiasis develops during or shortly after antibiotic course	Prophylactic antifungal during antibiotic therapy in susceptible women
Systemic corticosteroids	Immunosuppression; altered glucose metabolism	Increased risk of candidiasis; may mask inflammatory conditions	Monitor for fungal overgrowth; maintain vigilance for masked pathology
Combined hormonal contraceptives	Estrogen alters vaginal glycogen and environment	May increase candidiasis susceptibility in some women	Consider progestin-only or non-hormonal alternatives if recurrent candidiasis
Tamoxifen	Selective estrogen receptor modulator; mixed agonist/antagonist effects	Can cause vaginal discharge, dryness, or atrophic symptoms	Non-hormonal moisturizers; low-dose vaginal estrogen may be considered with oncology input
Aromatase inhibitors	Profound estrogen depletion	Severe vulvovaginal atrophy; dryness; dyspareunia	Non-hormonal lubricants and moisturizers; vaginal estrogen controversial
Antihistamines	Anticholinergic effect reduces secretions	Vaginal dryness	Vaginal moisturizers; consider alternative antihistamine
Isotretinoin	Reduces sebaceous gland activity; mucosal drying	Vaginal dryness; dyspareunia	Lubricants during treatment; typically resolves after discontinuation
Chemotherapy agents	Mucositis; immunosuppression; premature ovarian insufficiency	Vaginal dryness, mucositis, secondary candidiasis	Supportive care; antifungal prophylaxis if indicated
Topical medications (prolonged use)	Contact sensitization; skin atrophy (with steroids)	Contact dermatitis from vehicle or active ingredient; steroid atrophy	Minimize unnecessary topical applications; use steroids appropriately

Quick Reference: “If You See This, Think This”

Clinical Clue	Think This First	Next Step
Thick, white “cottage cheese” discharge with intense itch	Vulvovaginal candidiasis	Confirm with wet mount (hyphae/pseudohyphae) or yeast culture; antifungal treatment
Thin, gray discharge with fishy odor	Bacterial vaginosis	Amsel criteria or Nugent score; metronidazole or clindamycin
Frothy, yellow-green discharge with vulvar erythema	Trichomoniasis	Wet mount for motile trichomonads or NAAT; metronidazole; treat partner
White, crinkled “cigarette paper” skin in figure-of-eight	Lichen sclerosus	Clinical diagnosis often sufficient; biopsy if atypical; potent topical corticosteroid
Erosions with lacy white border; oral lesions	Erosive lichen planus	Biopsy for confirmation; potent topical steroids; may need systemic therapy
Postmenopausal with dryness and dyspareunia	Atrophic vaginitis / genitourinary syndrome of menopause	Examine for pale, thin epithelium; vaginal estrogen or non-hormonal moisturizers
Symptoms began after new hygiene product	Contact dermatitis (irritant or allergic)	Eliminate suspected product; topical steroid for acute inflammation; patch testing if allergic suspected
Severe pain with clusters of vesicles/ulcers	Herpes simplex virus	PCR or viral culture from lesion; antiviral therapy; screen for other sexually transmitted infections
Chronic itch with thickened, lichenified skin	Lichen simplex chronicus	Break itch-scratch cycle; topical steroids; consider underlying trigger
Pain and burning with normal examination	Vulvodynia / vestibulodynia	Q-tip test for allodynia; rule out other causes; multimodal treatment approach
Persistent unilateral lesion not responding to treatment	Vulvar intraepithelial neoplasia or carcinoma	Urgent biopsy; referral to gynecologic oncology if malignancy confirmed
Nocturnal perianal itching with vulvar extension	Pinworm infection (Enterobius)	Tape test; albendazole or mebendazole; treat household contacts

6. Diagnostic Investigations

A stepwise, cost-effective approach guided by clinical suspicion

Baseline Investigations for All Patients with Vulvovaginal Symptoms

Investigation	Purpose	What to Look For	Practical Points
Vaginal pH	Distinguish between candidiasis and bacterial causes	Normal (3.8-4.5): Suggests candidiasis or non-infectious cause Elevated (greater than 4.5): Suggests bacterial vaginosis, trichomoniasis, or atrophy	Use pH paper on lateral vaginal wall; avoid cervical mucus, blood, or semen which elevate pH
Wet mount microscopy (saline)	Identify infectious organisms and inflammatory cells	Clue cells (bacterial vaginosis); motile trichomonads; white blood cells; parabasal cells (atrophy)	Examine immediately for motile trichomonads; sensitivity for trichomoniasis only 50-60%
Wet mount microscopy (10% KOH)	Identify yeast; whiff test for bacterial vaginosis	Hyphae or pseudohyphae and budding yeast (candidiasis); fishy amine odor when KOH added (positive whiff test)	KOH lyses epithelial cells making yeast more visible; whiff test has 70% sensitivity for bacterial vaginosis
Vaginal discharge gram stain (if available)	Confirm bacterial vaginosis; identify yeast	Nugent score 0-3 normal, 4-6 intermediate, 7-10 bacterial vaginosis; gram-positive yeast and hyphae	Gold standard for bacterial vaginosis diagnosis; may not be available in all settings

Amsel Criteria for Bacterial Vaginosis (3 of 4 Required)

Thin, homogeneous, gray-white discharge — Adherent to vaginal walls
Vaginal pH greater than 4.5 — Measured from lateral vaginal wall
Positive whiff test — Fishy (amine) odor when 10% KOH added to discharge
Clue cells on wet mount — Epithelial cells with borders obscured by adherent bacteria (greater than 20% of epithelial cells)

Clinical Pearl: The presence of clue cells is the most specific criterion. If microscopy is not available, clinical diagnosis based on discharge characteristics and pH is acceptable for initiating treatment.

Targeted Investigations by Suspected Etiology

If Suspecting Vulvovaginal Candidiasis

First-Line Tests

Wet mount with KOH: Look for budding yeast, hyphae, or pseudohyphae; sensitivity 50-70%
Vaginal pH: Should be normal (less than 4.5); elevated pH makes candidiasis less likely

Second-Line Tests

Yeast culture: More sensitive than microscopy; identifies species; useful for recurrent or treatment-resistant cases
Candida speciation and susceptibility: Order if treatment failure; non-albicans species (especially C. glabrata) may require different treatment

If Suspecting Trichomoniasis

First-Line Tests

Nucleic acid amplification test (NAAT): Sensitivity greater than 95%; specificity greater than 95%; preferred test
Wet mount: Look for motile, pear-shaped trichomonads with flagella; sensitivity only 50-60%; examine immediately

Second-Line Tests

Trichomonas culture: Sensitivity 75-95%; takes 3-7 days; useful if NAAT unavailable
Rapid antigen test: Point-of-care option; sensitivity 80-90%
Screen for other sexually transmitted infections: Chlamydia, gonorrhea, HIV, syphilis

If Suspecting Sexually Transmitted Infection

Standard Screening Panel

Chlamydia trachomatis NAAT: Vaginal or endocervical swab, or urine
Neisseria gonorrhoeae NAAT: Same specimen as chlamydia
Trichomonas vaginalis NAAT: Vaginal swab preferred
HIV serology: Fourth-generation antigen/antibody test
Syphilis serology: RPR or VDRL with confirmatory treponemal test

If Ulceration Present

Herpes simplex virus PCR: From lesion swab; distinguishes HSV-1 from HSV-2
Syphilis darkfield microscopy or PCR: From chancre if available
Type-specific herpes serology: If PCR negative but clinical suspicion high; note: indicates past exposure, not necessarily cause of current lesion

If Suspecting Vulvar Dermatosis

When to Biopsy

Diagnosis uncertain after clinical examination
Failure to respond to appropriate treatment
Any pigmented lesion
Any persistent ulcer
Suspected vulvar intraepithelial neoplasia or malignancy
Atypical presentation of suspected lichen sclerosus or lichen planus

Biopsy Technique

Punch biopsy: 4mm punch is standard; local anesthesia; sample from active edge of lesion
Multiple biopsies: May be needed for multifocal disease
Avoid biopsy of: Erosions alone (non-diagnostic); sample adjacent tissue
Direct immunofluorescence: Order if bullous disease suspected (pemphigoid, pemphigus)

If Suspecting Atrophic Vaginitis

Clinical Assessment

Vaginal pH: Elevated (typically 5.0-7.0)
Vaginal maturation index: Increased parabasal and intermediate cells; decreased superficial cells
Clinical appearance: Pale, thin epithelium; loss of rugae; petechiae

Additional Considerations

Serum FSH and estradiol: Usually not needed if clinical picture clear; helpful in premature ovarian insufficiency
Rule out infection: Atrophy predisposes to bacterial overgrowth; wet mount to exclude co-existing vaginitis

If Suspecting Contact Dermatitis

Test	When to Order	Interpretation
Patch testing	Suspected allergic contact dermatitis not responding to avoidance; recurrent symptoms of unclear etiology	Identifies specific allergens (fragrances, preservatives, medications); helps guide avoidance strategies
Elimination trial	First-line approach; remove all potential irritants/allergens	Improvement within 2-4 weeks suggests contact etiology; reintroduce products one at a time

Systemic Investigations to Consider

Investigation	When to Order	Relevance
Fasting glucose or HbA1c	Recurrent vulvovaginal candidiasis (4 or more episodes per year); risk factors for diabetes	Undiagnosed or poorly controlled diabetes predisposes to candidiasis; HbA1c greater than 6.5% diagnostic
HIV testing	Recurrent or severe candidiasis; other sexually transmitted infections; risk factors	HIV-associated immunosuppression increases candidiasis risk and severity
Complete blood count	Suspected immunocompromise; severe or systemic symptoms	Leukopenia suggests immunosuppression; eosinophilia may suggest allergic component
Thyroid function tests	Lichen sclerosus (associated with autoimmune thyroid disease); unexplained symptoms	Up to 20% of lichen sclerosus patients have thyroid disease
Autoimmune panel	Lichen sclerosus with other autoimmune features; suspected autoimmune etiology	Anti-thyroid antibodies, anti-nuclear antibody; guides screening for associated conditions
Iron studies	Chronic symptoms; suspected lichen planus; oral involvement	Iron deficiency associated with oral lichen planus and angular cheilitis

Empiric Treatment Trials as Diagnostic Tools

Sequential Empiric Therapy Approach

When diagnosis is uncertain and laboratory testing is limited or inconclusive, empiric treatment trials can serve as diagnostic tools. Response (or lack thereof) provides valuable diagnostic information.

Antifungal trial: Fluconazole 150mg single dose or topical azole for 7 days — Response suggests vulvovaginal candidiasis
Antibiotic trial: Metronidazole 500mg twice daily for 7 days — Response suggests bacterial vaginosis or trichomoniasis
Topical corticosteroid trial: Mid-to-high potency steroid for 2-4 weeks — Response suggests inflammatory dermatosis (lichen sclerosus, lichen planus, contact dermatitis)
Vaginal estrogen trial: In postmenopausal women — Response within 2-4 weeks suggests atrophic vaginitis

Important: Empiric treatment should not replace appropriate diagnostic workup when resources are available. Document response to treatment to guide further management.

Practical Testing Algorithm

Stepwise Approach to Investigation:

All patients: Vaginal pH + wet mount microscopy (saline and KOH) + whiff test
If sexually active with new partner or STI concerns: Add NAAT for chlamydia, gonorrhea, and trichomonas; offer HIV and syphilis testing
If recurrent candidiasis (4 or more per year): Yeast culture with speciation; fasting glucose or HbA1c; consider HIV testing
If chronic symptoms not responding to treatment: Consider vulvar biopsy; patch testing if contact dermatitis suspected
If postmenopausal: Clinical assessment for atrophy usually sufficient; consider empiric vaginal estrogen trial
If pigmented, ulcerated, or persistent unilateral lesion: Vulvar biopsy is mandatory to rule out malignancy

When to Refer for Specialist Investigation

Clinical Scenario	Refer To	Purpose
Suspected vulvar malignancy or vulvar intraepithelial neoplasia	Gynecologic oncology	Biopsy, staging, definitive management
Complex vulvar dermatosis not responding to treatment	Vulvar dermatology clinic or dermatologist with vulvar expertise	Expert examination, biopsy interpretation, advanced treatment
Suspected allergic contact dermatitis requiring patch testing	Dermatology or allergy	Patch testing with vulvar-relevant allergen series
Vulvodynia / vestibulodynia not responding to initial management	Vulvar pain specialist, pelvic floor physical therapy	Multidisciplinary pain management approach
Recurrent vulvovaginal candidiasis with no identified cause	Infectious disease or immunology	Evaluation for underlying immunodeficiency

7. Pattern Recognition and Clinical Decision-Making

Practical algorithms and decision pathways

Step 1: Is This Urgent?

Clinical Scenario	Urgency Level	Immediate Action
Fever with pelvic pain and abnormal discharge	EMERGENT	Evaluate for pelvic inflammatory disease or tubo-ovarian abscess; obtain vital signs, pelvic examination, laboratory studies; consider hospitalization for intravenous antibiotics
Severe vulvar ulceration with urinary retention	EMERGENT	Likely primary herpes simplex virus; may need catheterization; start antiviral therapy immediately; assess for disseminated infection if immunocompromised
Rapidly expanding vulvar mass or ulcer	EMERGENT	Rule out necrotizing fasciitis (Fournier gangrene) if systemic toxicity; urgent surgical consultation; biopsy if malignancy suspected
Vulvar symptoms with systemic illness (fever, rash, lymphadenopathy)	URGENT	Consider primary syphilis, disseminated gonococcal infection, Behçet disease; comprehensive sexually transmitted infection screening; systemic evaluation
Persistent vulvar lesion not responding to treatment	URGENT	Biopsy to rule out vulvar intraepithelial neoplasia or carcinoma; refer to specialist if confirmed
Pregnant patient with vaginal symptoms	URGENT	Screen for bacterial vaginosis and trichomoniasis (associated with preterm birth); treat appropriately; avoid certain medications
Typical vaginitis symptoms without red flags	ROUTINE	Standard evaluation with history, examination, and office testing; initiate appropriate treatment
Chronic pruritus with known dermatosis on treatment	ROUTINE	Assess treatment response; adjust therapy as needed; schedule follow-up

Step 2: Classify by Duration and Presentation

Acute (Less Than 2 Weeks)

With abnormal discharge: Proceed to Algorithm A (Infectious Vaginitis)

Without discharge: Proceed to Algorithm B (Non-Infectious Acute)

Subacute (2-6 Weeks)

Partially treated infection: Re-evaluate and re-treat

Ongoing irritant exposure: Identify and eliminate

Evolving dermatosis: Consider biopsy

Chronic (Greater Than 6 Weeks)

Recurrent infections: Proceed to Algorithm C

Dermatosis suspected: Proceed to Algorithm D

Pain predominant: Proceed to Algorithm E (Vulvodynia)

Step 3: Follow the Appropriate Algorithm

Algorithm A: Acute Symptoms with Abnormal Discharge

Clinical Scenario	Most Likely Diagnosis	Action
Intense itch + thick white curd-like discharge + normal pH	Vulvovaginal candidiasis	Confirm with wet mount if possible; treat with fluconazole 150mg single dose or topical azole × 3-7 days
Fishy odor + thin gray discharge + pH greater than 4.5 + clue cells	Bacterial vaginosis	Meets Amsel criteria; treat with metronidazole 500mg twice daily × 7 days or vaginal gel
Frothy yellow-green discharge + vulvar erythema + pH greater than 4.5	Trichomoniasis	NAAT or wet mount; metronidazole 2g single dose; treat partner; screen for other sexually transmitted infections
Purulent discharge + cervical motion tenderness + fever	Pelvic inflammatory disease	Screen for gonorrhea and chlamydia; initiate empiric antibiotics; consider hospitalization
Mixed picture or uncertain	Possible co-infection	Complete testing for candida, bacterial vaginosis, trichomoniasis; treat based on results

Algorithm B: Acute Symptoms without Abnormal Discharge

Clinical Scenario	Most Likely Diagnosis	Action
Symptoms began after new product + well-demarcated erythema	Contact dermatitis (irritant or allergic)	Eliminate suspected irritant/allergen; cool compresses; medium-potency topical steroid × 1-2 weeks
Clusters of painful vesicles or ulcers + lymphadenopathy	Herpes simplex virus	PCR or viral culture from lesion; start antiviral (valacyclovir 1g twice daily × 7-10 days for primary)
Painless ulcer + inguinal lymphadenopathy	Primary syphilis	Darkfield or PCR from ulcer; serology; benzathine penicillin G 2.4 million units intramuscular single dose
Vulvar erythema and edema without discharge	Early candidiasis or contact irritation	Wet mount to check for yeast; trial of antifungal or barrier care based on findings

Algorithm C: Recurrent Vulvovaginal Candidiasis (4 or More Episodes Per Year)

Step	Action	Rationale
1. Confirm diagnosis	Culture during symptomatic episode; do not rely on history alone	Self-diagnosis is incorrect in up to 50% of cases; need to confirm yeast and identify species
2. Identify species	Request speciation from culture	Non-albicans species (especially Candida glabrata) may not respond to standard azoles
3. Screen for risk factors	Fasting glucose or HbA1c; HIV testing; review medications	Uncontrolled diabetes and immunosuppression predispose to recurrence
4. Induction therapy	Fluconazole 150mg every 72 hours × 3 doses	Achieve mycological cure before starting maintenance
5. Maintenance therapy	Fluconazole 150mg weekly × 6 months	Suppressive therapy reduces recurrence; 50% will recur after stopping
6. If azole-resistant	Boric acid 600mg vaginal capsule daily × 14 days; or topical amphotericin B	Alternative for non-albicans species or fluconazole-resistant strains

Algorithm D: Suspected Vulvar Dermatosis

Clinical Scenario	Most Likely Diagnosis	Action
White, atrophic skin + figure-of-eight pattern + architectural changes	Lichen sclerosus	Clinical diagnosis often sufficient; start clobetasol 0.05% ointment daily × 4 weeks, then taper; biopsy if atypical
Erosions with lacy white border + oral involvement	Erosive lichen planus	Biopsy to confirm; potent topical steroid; may need systemic therapy (tacrolimus, systemic steroids)
Lichenified, thickened skin + evidence of scratching	Lichen simplex chronicus	Break itch-scratch cycle; potent topical steroid; address underlying cause; sedating antihistamine at night
Well-demarcated pink plaques + psoriasis elsewhere	Vulvar psoriasis	Low-to-medium potency topical steroid (thin skin); calcineurin inhibitors (tacrolimus); treat other sites
Postmenopausal + thin, pale epithelium + dryness	Atrophic vaginitis / genitourinary syndrome of menopause	Vaginal estrogen cream or tablet; non-hormonal moisturizers; reassess in 4-6 weeks

Algorithm E: Suspected Vulvodynia / Vestibulodynia

Step	Action	Rationale
1. Exclude other causes	Thorough history, examination, and testing for infections and dermatoses	Vulvodynia is a diagnosis of exclusion; must rule out treatable causes
2. Confirm allodynia	Positive Q-tip test with pain at vestibule	Reproducible pain with light touch confirms vestibular hypersensitivity
3. First-line treatment	Vulvar care measures; topical lidocaine 5% before intercourse; pelvic floor physical therapy	Address peripheral factors; many patients have pelvic floor hypertonicity
4. Second-line treatment	Tricyclic antidepressant (amitriptyline 10-75mg nightly) or gabapentinoid (gabapentin 300-3600mg daily)	Neuromodulation for central sensitization; start low, titrate slowly
5. Refractory cases	Refer to vulvar pain specialist; consider vestibulectomy for localized vestibulodynia	Multidisciplinary approach; surgery has 60-90% success rate in selected patients

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Next Step
Patient self-treated with over-the-counter antifungal without relief	Do not assume candidiasis; perform proper evaluation	Wet mount, pH, consider NAAT for trichomoniasis; culture if microscopy negative but candidiasis suspected
Recurrent bacterial vaginosis despite treatment	Confirm diagnosis; extend treatment duration	Metronidazole gel twice weekly × 4-6 months for suppression; consider boric acid; evaluate for biofilm
Symptoms persist despite negative testing	Re-examine; consider dermatosis or vulvodynia	Biopsy if visible lesion; Q-tip test; empiric trial of topical steroid; refer if unclear
Patient allergic to metronidazole	For bacterial vaginosis: Clindamycin 300mg twice daily × 7 days or vaginal cream	For trichomoniasis: Desensitization protocol may be needed; consult infectious disease
Pregnant patient with bacterial vaginosis	Treat to reduce preterm birth risk (especially if history of preterm birth)	Metronidazole 500mg twice daily × 7 days (safe in pregnancy) or metronidazole 250mg three times daily × 7 days
Pregnant patient with trichomoniasis	Treat with metronidazole 2g single dose (safe in all trimesters)	Partner treatment essential; retest at 3 months
Patient with lichen sclerosus not responding to clobetasol	Confirm compliance; check technique; ensure adequate duration	Biopsy to confirm diagnosis and rule out malignancy; consider intralesional steroids; refer to specialist
Patient requests treatment but refuses examination	Counsel on importance of examination; discuss telemedicine limitations	If must treat empirically, single-dose fluconazole is reasonable for uncomplicated symptoms; advise follow-up if no improvement

Troubleshooting Refractory Vulvovaginal Symptoms

Ask These Questions When Treatment Fails

Is the diagnosis correct? — Re-examine and re-test; consider conditions that mimic the presumed diagnosis; biopsy if indicated
Was treatment adequate? — Correct drug? Correct dose? Correct duration? Correct route?
Was compliance good? — Ask specifically about missed doses, early discontinuation, or incorrect application
Is there an ongoing trigger? — Continued irritant exposure, uncontrolled diabetes, ongoing antibiotic use, partner reinfection
Are there multiple overlapping causes? — Co-infection is common; dermatosis may coexist with infection
Is this a resistant organism? — Culture with susceptibility testing; consider non-albicans candida, metronidazole-resistant trichomoniasis
Is this vulvodynia? — If no identifiable cause despite thorough evaluation, consider neuropathic pain syndrome
Does this need specialist referral? — Complex dermatoses, recurrent infections, suspected malignancy, vulvodynia

8. Clinical Pearls and Pitfalls

Practical wisdom — learn from successes and avoid common mistakes

Must-Know Clinical Pearls

Self-diagnosis is wrong half the time: Studies show that women who self-diagnose vulvovaginal candidiasis are correct only 50% of the time. Always confirm the diagnosis with examination and testing when possible before treating.

pH is your first clue: Vaginal pH is a simple, inexpensive test that immediately narrows the differential. Normal pH (less than 4.5) suggests candidiasis or non-infectious cause. Elevated pH (greater than 4.5) suggests bacterial vaginosis, trichomoniasis, or atrophy.

Lichen sclerosus spares the vagina: A key distinguishing feature — lichen sclerosus affects the vulva and perianal area but stops at Hart’s line and does not involve the vaginal mucosa. If there are vaginal erosions or synechiae, consider lichen planus instead.

Check the mouth in erosive vulvar disease: Oral lichen planus (lacy white Wickham striae, erosions) coexists with vulvovaginal lichen planus in approximately 50% of cases. Oral examination can clinch the diagnosis.

Candidiasis can occur at normal pH: Unlike bacterial vaginosis and trichomoniasis, vulvovaginal candidiasis typically occurs when vaginal pH is normal. If pH is elevated and you suspect yeast, look for co-infection with bacterial vaginosis.

NAAT has revolutionized trichomoniasis diagnosis: Wet mount microscopy for trichomonads has only 50-60% sensitivity. NAAT testing (sensitivity greater than 95%) should be the preferred diagnostic method and has revealed that trichomoniasis is far more common than previously recognized.

Empiric treatment response is diagnostic information: Response to antifungals supports candidiasis; response to metronidazole supports bacterial vaginosis or trichomoniasis; response to topical steroids supports dermatosis. No response to anything suggests vulvodynia or incorrect diagnosis.

Partner treatment is essential for trichomoniasis: Trichomoniasis is a sexually transmitted infection with high reinfection rates if partners are not treated simultaneously. Always provide expedited partner therapy or ensure partner is treated.

Critical Pitfalls to Avoid

Treating “yeast infection” without confirmation: Repeated empiric antifungal treatment without diagnosis leads to delayed treatment of the actual condition, unnecessary medication exposure, and potential azole resistance. Confirm the diagnosis.

Missing lichen sclerosus because the skin looks “normal”: Early lichen sclerosus may present with pruritus before classic white, atrophic changes appear. If examination is unrevealing but symptoms persist, re-examine during a flare or consider biopsy.

Not biopsying persistent or atypical vulvar lesions: Vulvar squamous cell carcinoma can arise in lichen sclerosus (4-6% lifetime risk) and may initially appear as non-healing erosion or thickened plaque. Have a low threshold for biopsy, especially in elderly patients.

Forgetting about non-albicans candida: In recurrent candidiasis not responding to standard azole therapy, Candida glabrata or other non-albicans species may be responsible. These require culture-based diagnosis and alternative treatments (boric acid, amphotericin B).

Attributing all symptoms to “menopause” in postmenopausal women: While atrophic vaginitis is common, postmenopausal women are also at increased risk for lichen sclerosus, lichen planus, and vulvar malignancy. Do not assume atrophy without proper examination.

Stopping lichen sclerosus treatment after symptoms resolve: Lichen sclerosus is a chronic condition requiring long-term maintenance therapy. Stopping treatment leads to relapse and progressive architectural damage. Patients need ongoing potent topical corticosteroid use.

Missing the contact dermatitis trigger: Patients often do not consider “natural” products, long-used products, or indirect exposures (laundry detergent on underwear, partner’s products). Take a detailed product history and consider elimination trials.

Dismissing vulvodynia as “nothing wrong”: Normal examination does not mean no pathology. Vulvodynia is a real condition with neurobiological underpinnings causing significant suffering. Validate the patient’s experience and offer appropriate treatment.

Key Takeaways

The three most common infectious causes of vulvovaginal symptoms are vulvovaginal candidiasis, bacterial vaginosis, and trichomoniasis — but up to 30% of symptomatic women have non-infectious causes.
Vaginal pH is a simple bedside test that immediately helps distinguish candidiasis (normal pH) from bacterial vaginosis and trichomoniasis (elevated pH).
Self-diagnosis of vulvovaginal candidiasis is incorrect approximately 50% of the time — always confirm the diagnosis before initiating treatment when possible.
For chronic vulvar pruritus, think beyond infection: lichen sclerosus, lichen planus, contact dermatitis, and atrophic vaginitis are common causes.
Lichen sclerosus requires lifelong maintenance therapy with potent topical corticosteroids and surveillance for malignant transformation.
Recurrent vulvovaginal candidiasis (4 or more episodes per year) warrants investigation for underlying causes (diabetes, immunosuppression) and may require prolonged suppressive antifungal therapy.
NAAT testing has significantly improved diagnosis of trichomoniasis compared to wet mount microscopy — use it when available.
A normal vulvovaginal examination does not exclude significant pathology — many conditions (candidiasis, bacterial vaginosis, vulvodynia, early dermatoses) may have minimal or no visible findings.
Biopsy any persistent, unilateral, pigmented, or treatment-resistant vulvar lesion to rule out vulvar intraepithelial neoplasia or carcinoma.
Vulvodynia is a diagnosis of exclusion characterized by chronic vulvar pain without identifiable cause — it requires a multimodal treatment approach including pelvic floor therapy and neuromodulating medications.

Quick Reference Algorithm

Systematic Approach to Vulvovaginal Pruritus and Irritation:

Assess urgency: Identify red flags (fever, ulceration, mass, systemic symptoms) requiring urgent evaluation
Take a focused history: Use the “VULVAR” mnemonic — Validate and characterize, Understand discharge, Location, Variations and triggers, Associated symptoms, Risk factors and responses
Examine systematically: General inspection, external genitalia, speculum examination, bimanual examination; check oral mucosa and skin elsewhere
Perform bedside tests: Vaginal pH, wet mount microscopy (saline and KOH), whiff test
Formulate differential: Use duration (acute versus chronic), discharge characteristics, pH, and examination findings to narrow diagnosis
Order targeted investigations: NAAT for sexually transmitted infections, yeast culture if recurrent, biopsy if dermatosis suspected or lesion persistent
Treat the specific cause: Antifungals for candidiasis, metronidazole for bacterial vaginosis and trichomoniasis, topical steroids for dermatoses, vaginal estrogen for atrophy
Arrange follow-up: Reassess response; if treatment fails, reconsider diagnosis and consider specialist referral